KemPharm (NASDAQ:KMPH) Announces Quarterly Earnings Results

KemPharm (NASDAQ:KMPH) posted its earnings results on Tuesday. The specialty pharmaceutical company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.09, Fidelity Earnings reports.

KMPH stock traded down $0.13 during midday trading on Wednesday, hitting $0.97. The stock had a trading volume of 10,048 shares, compared to its average volume of 156,791. The firm has a market capitalization of $32.80 million, a price-to-earnings ratio of -0.40 and a beta of 1.39. KemPharm has a 52 week low of $1.00 and a 52 week high of $5.47. The stock’s 50-day simple moving average is $1.46.

A number of equities research analysts have issued reports on the company. Oppenheimer decreased their target price on KemPharm from $8.00 to $3.00 and set an “outperform” rating for the company in a research report on Thursday, May 23rd. HC Wainwright started coverage on KemPharm in a research report on Wednesday, June 19th. They issued a “buy” rating and a $3.00 price objective for the company. Finally, ValuEngine raised KemPharm from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $5.50.

KemPharm Company Profile

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.

See Also: Percentage Gainers

Earnings History for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with's FREE daily email newsletter.

Leave a Reply